COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report
Corresponding Author
Massimo Breccia
Department of Translational and Precision Medicine, Sapienza University, Roma, Italy
Correspondence: Massimo Breccia, Hematology, Department of Translational and Precision Medicine, Sapienza University, Via Benevento 6, Rome 00161, Italy.
E-mail: [email protected]
Search for more papers by this authorElisabetta Abruzzese
Sant Eugenio Hospital, Hematology, Roma, Italy
Search for more papers by this authorVincenzo Accurso
UO di Ematologia con Trapianto, AU Policlinico Paolo Giaccone, Palermo, Italy
Search for more papers by this authorImmacolata Attolico
UO Ematologia con Trapianto, Università degli Studi di Bari Aldo Moro, Bari, Italy
Search for more papers by this authorSara Barulli
Divisione di Ematologia di Muraglia, CTMO Ospedale San Salvatore, Pesaro, Italy
Search for more papers by this authorMicaela Bergamaschi
Ematologia, Ospedale Santa Corona, Pietra Ligure, Italy
Search for more papers by this authorGianni Binotto
Ematologia ed Immunologia Clinica, Università degli Studi di Padova, Padova, Italy
Search for more papers by this authorMonica Bocchia
U.O.C. Ematologia e Trapianti, A.O. Senese – Policlinico ‘Le Scotte’, Siena, Italy
Search for more papers by this authorMassimiliano Bonifacio
Divisione di Ematologia, Istituti Ospitalieri di Verona, Policlinico G.B. Rossi, Verona, Italy
Search for more papers by this authorGiovanni Caocci
CTMO – Ematologia, Ospedale ‘Businco’, Cagliari, Italy
Search for more papers by this authorIsabella Capodanno
Ematologia, Azienda Unità Sanitaria Locale-IRCCS, Reggio Emilia, Italy
Search for more papers by this authorFausto Castagnetti
Istituto di Ematologia ‘Lorenzo e A. Seragnoli’, Policlinico S. Orsola-Malpighi, Bologna, Italy
Search for more papers by this authorFrancesco Cavazzini
Ematologia, Arcispedale Sant'Anna, Ferrara, Italy
Search for more papers by this authorElena Crisà
S.C.D.U. Ematologia – DIMECS e Dipartimento Oncologico, Università del Piemonte Orientale Amedeo Avogadro, Novara, Italy
Search for more papers by this authorMonica Crugnola
Ematologia, Università degli Studi di Parma, Parma, Italy
Search for more papers by this authorMaria Stella De Candia
UOC Ematologia con Trapianto, Brindisi Hospital, Brindisi, Italy
Search for more papers by this authorChiara Elena
Ematologia, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy
Search for more papers by this authorCarmen Fava
A.S.O. Ordine Mauriziano, P.O. Umberto I, Struttura Complessa a Direzione Universitaria-Ematologia e Terapie Cellulari, Torino, Italy
Search for more papers by this authorSara Galimberti
Ematologia, Università di Pisa – Azienda Ospedaliera Pisana, Pisa, Italy
Search for more papers by this authorAntonella Gozzini
Unità di Ricerca e di Malattie del Sangue, Ematologia San Luca Vecchio, Firenze, Italy
Search for more papers by this authorGabriele Gugliotta
Istituto di Ematologia ‘Lorenzo e A. Seragnoli’, Policlinico S. Orsola-Malpighi, Bologna, Italy
Search for more papers by this authorTamara Intermesoli
Hematology, Bergamo Hospital, Bergamo, Italy
Search for more papers by this authorAlessandra Iurlo
UOC Ematologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
Search for more papers by this authorGaetano La Barba
U.O. Ematologia Clinica, Azienda USL di Pescara, Pescara, Italy
Search for more papers by this authorRoberto Latagliata
Ematologia, Ospedale Belcolle, Viterbo, Italy
Search for more papers by this authorSabrina Leonetti Crescenzi
Ematologia, Ospedale S. Giovanni Addolorata, Roma, Italy
Search for more papers by this authorLuciano Levato
Ematologia, Ospedale Catanzaro, Catanzaro, Italy
Search for more papers by this authorAlessandro Lucchesi
Ematologia, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) ‘Dino Amadori’, Meldola, Italy
Search for more papers by this authorLuigiana Luciano
Ematologia, Azienda Ospedaliera Universitaria – Università degli Studi di Napoli ‘Federico II’, Napoli, Italy
Search for more papers by this authorFrancesca Lunghi
Ematologia, Ospedale S. Raffaele, Milano, Italy
Search for more papers by this authorDebora Luzi
Ematologia, A.O. Santa Maria – Terni S.C Oncoematologia, Terni, Italy
Search for more papers by this authorAlessandra Malato
Ematologia, Ospedali Riuniti ‘Villa Sofia-Cervello’, Palermo, Italy
Search for more papers by this authorMaria Cristina Miggiano
Ematologia, Ospedale Vicenza, Vicenza, Italy
Search for more papers by this authorPatrizia Pregno
Dipartimento di Oncologia ed Ematologia S.C. Ematologia 2, A.O. Città della Salute e della Scienza di Torino S. G. Battista, Torino, Italy
Search for more papers by this authorGiovanna Rege-Cambrin
Dipartimento di Scienze Cliniche e Biologiche, Ospedale S. Luigi Gonzaga-Medicina Interna 2, Orbassano, Italy
Search for more papers by this authorGianantonio Rosti
Ematologia, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) ‘Dino Amadori’, Meldola, Italy
Search for more papers by this authorSabina Russo
Dipartimento di Medicina Interna, Azienda Ospedaliera Universitaria – Policlinico G. Martino, Messina, Italy
Search for more papers by this authorAnna Rita Scortechini
Ematologia, Azienda Ospedaliero – Universitaria Ospedali Riuniti, Ancona, Italy
Search for more papers by this authorFederica Sorà
Ematologia, Policlinico Gemelli – Università Cattolica del Sacro Cuore, Roma, Italy
Search for more papers by this authorFabio Stagno
Hematology Section and BMT Unit, AOU Policlinico ‘Rodolico-San Marco’, Catania, Italy
Search for more papers by this authorMario Tiribelli
Clinica Ematologica-Centro Trapianti e Terapie cellulari, Azienda Ospedaliero-Universitaria, Udine, Italy
Search for more papers by this authorRobin Foà
Department of Translational and Precision Medicine, Sapienza University, Roma, Italy
Search for more papers by this authorGiuseppe Saglio
A.S.O. Ordine Mauriziano, Struttura Complessa a Direzione Universitaria-Ematologia e Terapie Cellulari-, P.O. Umberto I, Torino, Italy
Search for more papers by this authorCorresponding Author
Massimo Breccia
Department of Translational and Precision Medicine, Sapienza University, Roma, Italy
Correspondence: Massimo Breccia, Hematology, Department of Translational and Precision Medicine, Sapienza University, Via Benevento 6, Rome 00161, Italy.
E-mail: [email protected]
Search for more papers by this authorElisabetta Abruzzese
Sant Eugenio Hospital, Hematology, Roma, Italy
Search for more papers by this authorVincenzo Accurso
UO di Ematologia con Trapianto, AU Policlinico Paolo Giaccone, Palermo, Italy
Search for more papers by this authorImmacolata Attolico
UO Ematologia con Trapianto, Università degli Studi di Bari Aldo Moro, Bari, Italy
Search for more papers by this authorSara Barulli
Divisione di Ematologia di Muraglia, CTMO Ospedale San Salvatore, Pesaro, Italy
Search for more papers by this authorMicaela Bergamaschi
Ematologia, Ospedale Santa Corona, Pietra Ligure, Italy
Search for more papers by this authorGianni Binotto
Ematologia ed Immunologia Clinica, Università degli Studi di Padova, Padova, Italy
Search for more papers by this authorMonica Bocchia
U.O.C. Ematologia e Trapianti, A.O. Senese – Policlinico ‘Le Scotte’, Siena, Italy
Search for more papers by this authorMassimiliano Bonifacio
Divisione di Ematologia, Istituti Ospitalieri di Verona, Policlinico G.B. Rossi, Verona, Italy
Search for more papers by this authorGiovanni Caocci
CTMO – Ematologia, Ospedale ‘Businco’, Cagliari, Italy
Search for more papers by this authorIsabella Capodanno
Ematologia, Azienda Unità Sanitaria Locale-IRCCS, Reggio Emilia, Italy
Search for more papers by this authorFausto Castagnetti
Istituto di Ematologia ‘Lorenzo e A. Seragnoli’, Policlinico S. Orsola-Malpighi, Bologna, Italy
Search for more papers by this authorFrancesco Cavazzini
Ematologia, Arcispedale Sant'Anna, Ferrara, Italy
Search for more papers by this authorElena Crisà
S.C.D.U. Ematologia – DIMECS e Dipartimento Oncologico, Università del Piemonte Orientale Amedeo Avogadro, Novara, Italy
Search for more papers by this authorMonica Crugnola
Ematologia, Università degli Studi di Parma, Parma, Italy
Search for more papers by this authorMaria Stella De Candia
UOC Ematologia con Trapianto, Brindisi Hospital, Brindisi, Italy
Search for more papers by this authorChiara Elena
Ematologia, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy
Search for more papers by this authorCarmen Fava
A.S.O. Ordine Mauriziano, P.O. Umberto I, Struttura Complessa a Direzione Universitaria-Ematologia e Terapie Cellulari, Torino, Italy
Search for more papers by this authorSara Galimberti
Ematologia, Università di Pisa – Azienda Ospedaliera Pisana, Pisa, Italy
Search for more papers by this authorAntonella Gozzini
Unità di Ricerca e di Malattie del Sangue, Ematologia San Luca Vecchio, Firenze, Italy
Search for more papers by this authorGabriele Gugliotta
Istituto di Ematologia ‘Lorenzo e A. Seragnoli’, Policlinico S. Orsola-Malpighi, Bologna, Italy
Search for more papers by this authorTamara Intermesoli
Hematology, Bergamo Hospital, Bergamo, Italy
Search for more papers by this authorAlessandra Iurlo
UOC Ematologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
Search for more papers by this authorGaetano La Barba
U.O. Ematologia Clinica, Azienda USL di Pescara, Pescara, Italy
Search for more papers by this authorRoberto Latagliata
Ematologia, Ospedale Belcolle, Viterbo, Italy
Search for more papers by this authorSabrina Leonetti Crescenzi
Ematologia, Ospedale S. Giovanni Addolorata, Roma, Italy
Search for more papers by this authorLuciano Levato
Ematologia, Ospedale Catanzaro, Catanzaro, Italy
Search for more papers by this authorAlessandro Lucchesi
Ematologia, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) ‘Dino Amadori’, Meldola, Italy
Search for more papers by this authorLuigiana Luciano
Ematologia, Azienda Ospedaliera Universitaria – Università degli Studi di Napoli ‘Federico II’, Napoli, Italy
Search for more papers by this authorFrancesca Lunghi
Ematologia, Ospedale S. Raffaele, Milano, Italy
Search for more papers by this authorDebora Luzi
Ematologia, A.O. Santa Maria – Terni S.C Oncoematologia, Terni, Italy
Search for more papers by this authorAlessandra Malato
Ematologia, Ospedali Riuniti ‘Villa Sofia-Cervello’, Palermo, Italy
Search for more papers by this authorMaria Cristina Miggiano
Ematologia, Ospedale Vicenza, Vicenza, Italy
Search for more papers by this authorPatrizia Pregno
Dipartimento di Oncologia ed Ematologia S.C. Ematologia 2, A.O. Città della Salute e della Scienza di Torino S. G. Battista, Torino, Italy
Search for more papers by this authorGiovanna Rege-Cambrin
Dipartimento di Scienze Cliniche e Biologiche, Ospedale S. Luigi Gonzaga-Medicina Interna 2, Orbassano, Italy
Search for more papers by this authorGianantonio Rosti
Ematologia, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) ‘Dino Amadori’, Meldola, Italy
Search for more papers by this authorSabina Russo
Dipartimento di Medicina Interna, Azienda Ospedaliera Universitaria – Policlinico G. Martino, Messina, Italy
Search for more papers by this authorAnna Rita Scortechini
Ematologia, Azienda Ospedaliero – Universitaria Ospedali Riuniti, Ancona, Italy
Search for more papers by this authorFederica Sorà
Ematologia, Policlinico Gemelli – Università Cattolica del Sacro Cuore, Roma, Italy
Search for more papers by this authorFabio Stagno
Hematology Section and BMT Unit, AOU Policlinico ‘Rodolico-San Marco’, Catania, Italy
Search for more papers by this authorMario Tiribelli
Clinica Ematologica-Centro Trapianti e Terapie cellulari, Azienda Ospedaliero-Universitaria, Udine, Italy
Search for more papers by this authorRobin Foà
Department of Translational and Precision Medicine, Sapienza University, Roma, Italy
Search for more papers by this authorGiuseppe Saglio
A.S.O. Ordine Mauriziano, Struttura Complessa a Direzione Universitaria-Ematologia e Terapie Cellulari-, P.O. Umberto I, Torino, Italy
Search for more papers by this author*Robin Foà and Giuseppe Saglio contributed equally.
Summary
Limited information is available on the impact of the COVID-19 pandemic on the management of chronic myeloid leukaemia (CML). The Campus CML network collected retrospective information on 8 665 CML patients followed at 46 centres throughout Italy during the pandemic between February 2020 and January 2021. Within this cohort, we recorded 217 SARS-CoV-2-positive patients (2·5%). Most patients (57%) were diagnosed as having SARS-CoV-2 infection during the second peak of the pandemic (September 2020 to January 2021). The majority (35%) was aged between 50 and 65 years with a male prevalence (73%). Fifty-six percent of patients presented concomitant comorbidities. The median time from CML diagnosis to SARS-CoV-2 infection was six years (three months to 18 years). Twenty-one patients (9·6%) required hospitalization without the need of respiratory assistance, 18 (8·2%) were hospitalized for respiratory assistance, 8 (3·6%) were admitted to an intensive care unit, while 170 (78%) were only quarantined. Twenty-three percent of patients discontinued tyrosine kinase inhibitor (TKI) therapy during the infection. Twelve patients died due to COVID-19 with a mortality rate of 5·5% in the positive cohort and of 0·13% in the whole cohort. We could also document sequelae caused by the SARS-CoV-2 infection and an impact of the pandemic on the overall management of CML patients.
References
- 1He W, Chen L, Chen L, Yuan G, Fang Y, Chen W, et al. COVID-19 in persons with hematological cancers. Leukemia. 2020; 34(6): 1637–45.
- 2Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicenter, cohort study. Lancet Hematology. 2020; 7(10): e737–45.
- 3Li W, Wang D, Guo J, Yuan G, Yang Z, Gale RP, et al. COVID-19 in persons with chronic myeloid leukemia. Leukemia. 2020; 34(7): 1799–804.
- 4Breccia M, Abruzzese E, Bocchia M, Bonifacio M, Castagnetti F, Fava C, et al. Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey. Leukemia. 2020; 34(8): 2260–1.
- 5Ector GICG, Huijskens EGW, Blijlevens NMA, Westerweel PE. Prevalence of COVID-19 diagnosis in Dutch CML patients during the 2020 SARS-CoV2 pandemic. A prospective Cohort study. Leukemia. 2020; 34(9): 2533–5.
- 6Başcı S, Ata N, Altuntaş F, Yiğenoğlu TN, Dal MS, Korkmaz S, et al. Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors. J Oncol Pharm Pract. 2020; 26(7): 1676–82.
- 7Cross NCP, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E, et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia. 2015; 29(5): 999–1003.
- 8Samadizadeh S, Masoudi M, Rastegar M, Salimi V, Shahbaz MB, Tahamtan A. COVID-19: why dose disease severity vaty among individuals? Respir Med. 2021; 180:106356.
- 9Coleman CM, Sisk JM, Mingo RM, Nelson EA, White JM, Frieman MB. Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus fusion. J Virol. 2016; 90: 8924–33.
- 10Sisk JM, Frieman MB, Machamer CE. Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors. J Gen Virol. 2018; 99: 619–30.
- 11Foà R, Bonifacio M, Chiaretti S, Curti A, Candoni A, Fava C, et al. Philadelphia-positive acute lymphoblastic leukemia (ALL) in Italy during the COVID-19 pandemic: a Campus ALL study. Br J Haematol. 2020; 190: e3–5.
- 12Nguyen DD, Gao K, Chen J, Wang R, Wei GW. Potentially highly potent drugs for 2019-nCoV. bioRxiv. https://doi.org/10.1101/2020.02.05.936013
10.1101/2020.02.05.936013 Google Scholar
- 13Galimberti S, Petrini M, Baratè C, Ricci F, Balducci S, Grassi S, et al. Tyrosine kinase inhibitors play an antiviral action in patients affected by chronic myeloid leukemia: a possible model supporting their use in the fight against SARS-CoV-2. Front Oncol. 2020; 10: 1428.
- 14Rea D, Mauro MJ, Cortes JE, Jiang Q, Pagnano KB, Ongondi M, et al. COVID-19 in patients with chronic myeloid leukemia: results from the international CML Foundation (iCMLf) CML and COVID-19 (CANDID) study. Blood. 2020; 136(s1): 649.
- 15 Ministry of Health. Characteristics of COVID-19 patients dying in Italy. Available from: Epicentro.iss.it/en/coronavirus/sars-cov-2-analysis-of-deaths
- 16Bonifacio M, Binotto G, Tiribelli M, Miggiano MC, Trawinska MM, Scaffidi L, et al. Serological prevalence of Sars-Cov2 infection among chronic myeloid leukemia patients undergoing tyrosine kinase inhibitor treatment in Italy (COVID-19-HEM study). Blood. 2020; 136(s1): 1235.
- 17Claudiani S, Rosadas C, McClure M, Khan M, Tedder RS, Innes AJ, et al. Prevalence of SARS-Cov2 infection in patients with chronic myeloid leukemia. Blood. 2020; 136(s1): 3065.
- 18Halpin SJ, McIvor C, Whyatt G, Adams A, Harvey O, McLean L, et al. Post-discharge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. J Med Virol. 2021; 93: 1013–22.
